Head-to-Head: which biologic works better for tough psoriatic arthritis?

NCT ID NCT04632927

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two biologic drugs, secukinumab and ustekinumab, in 119 adults with active psoriatic arthritis who had not responded to or could not tolerate TNFα-inhibitor treatment. The main goal was to see which drug better improved physical function over 28 weeks. Researchers also looked at skin clearance and other outcomes. The trial is complete, and results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (a biologic drug) and Ustekinumab (a biologic drug)
What this could lead to: If secukinumab works better than ustekinumab, it could offer a new treatment option for people with psoriatic arthritis who have not responded to other therapies.
What could go wrong: This is a completed Phase 3 trial with 119 participants, so results are more reliable than early-phase studies. However, individual responses vary, and both drugs have known side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS

Contacts and locations

Locations

Novartis Investigative Site

Rendsburg, Schleswig-Holstein, 24768, Germany
Novartis Investigative Site

Aachen, 52074, Germany
Novartis Investigative Site

Bad Bentheim, 48455, Germany
Novartis Investigative Site

Bad Doberan, 18209, Germany
Novartis Investigative Site

Berlin, 12435, Germany
Novartis Investigative Site

Berlin, 13125, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Bochum, 44791, Germany
Novartis Investigative Site

Cologne, 50937, Germany
Novartis Investigative Site

Cologne, 51149, Germany
Novartis Investigative Site

Cottbus, 03042, Germany
Novartis Investigative Site

Dresden, 01067, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Ehringshausen, 35630, Germany
Novartis Investigative Site

Erlangen, 91056, Germany
Novartis Investigative Site

Frankfurt, 60590, Germany
Novartis Investigative Site

Freiburg im Breisgau, 79106, Germany
Novartis Investigative Site

Gommern, 39245, Germany
Novartis Investigative Site

Göttingen, 37075, Germany
Novartis Investigative Site

Hamburg, 22391, Germany
Novartis Investigative Site

Herne, 44649, Germany
Novartis Investigative Site

Leipzig, 04103, Germany
Novartis Investigative Site

Magdeburg, 39104, Germany
Novartis Investigative Site

Magdeburg, 39110, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

München, 81541, Germany
Novartis Investigative Site

Planegg, 82152, Germany
Novartis Investigative Site

Ratingen, 40878, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.